Ipsen telegraphed plans to acquire Epizyme and the FDA-approved Tazverik in June 2022, two years after the med’s clearance in the U.S. as both an epithelioid sarcoma and follicular lymphoma treatment.

Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz as a first-line treatment for non-small cell lung cancer.

Rising rates of breast cancer among working-age Australian women have prompted urgent calls for action to address the growing impact of financial ...

Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that Itovebi® (inavolisib) is the first breast cancer therapy ...

Read more about how occupational therapy interventions mitigate chemotherapy-induced cognitive impairment among women with breast cancer.

This study evaluates inclusion of National Comprehensive Cancer Network (NCCN) guideline recommended biomarkers for metastatic non–small cell lung cancer (NSCLC) in commercially available targeted ...

Factors that drive the growth of the global oncology/cancer drugs market include rise in awareness among the population about the treatment options of cancer, increase in prevalence of cancer disease, ...

With a total budget of EUR 21.5 million, the four-year SHERPA research project is coordinated by Philips and co-funded by the EU Innovative Health Initiative (IHI) and industry partners The project ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of anticoagulants, investigators found no evidence of an increase in patients’ ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies. However, nearly half of patients show limited ...

"Since cancer happens where there are cells in your body, why have I never seen such thing as heart/muscles cancer?" ...